Welcome to 3i

For US regulatory reasons, US Residents are not to enter this site without the express permission of 3i Group plc, and 3i Group plc is not offering any securities or services in the United States or to US Residents through this site. (The term "US Residents" is defined in the detailed terms and conditions set out in the Terms and conditions page).

I am not a US resident (or I am, but I have 3i Group plc's express permission to use this site) and I accept the terms and conditions.

Terms and conditions

Gettyimages 1727754950 MARKEN

Marken

  • Sector Services and Software
  • Year invested 2006
  • Location UK
  • Status Realised

Marken is a specialist express logistics and support services provider to the biopharmaceutical industry.

Visit marken.com

Overview

Its services include the movement of biological samples on a global basis, the export of trial medication, vaccines and clinical trial material, regulatory advice, protocol support, cold-chain management and investigator liaison.

How we added value

  • Delivered an ambitious growth strategy and achieved a growth rate of over 30%
  • Increased operating margins through both revenue growth and cost savings
  • Strengthened the management team and introduced sector expert, Mel Porter, to the board as NXD
  • Leveraged 3i’s global network to support organic growth while actively seeking out bolt-on acquisitions
  • Established operations in China
  • Expanded US market share and targeted US-based pharma companies

3i managed to pre-empt what was going to be a highly competitive auction by the speed with which it completed its due diligence and was ready to execute a contract. 3i became the preferred acquirer with management, and was quickly able to conclude the deal.

Jonathan Rowland , MD, Citigroup

Regulatory information
This transaction involved a recommendation of 3i Investments plc.